PureTech Health plc (LON:PRTC)
London · Delayed Price · Currency is GBP · Price in GBX 114.20
+0.40 (0.35%)
Oct 15, 2026, 2:39 PM GMT
PureTech Health Revenue
In the year 2025, PureTech Health had annual revenue of $4.66M USD, down -3.50%. PureTech Health had revenue of $2.81M in the half year ending December 31, 2025, with 1,460.00% growth. That makes PureTech Health the 39,126th largest company in the world by revenue and 756th in the United Kingdom.
Revenue
$4.66M
Revenue Growth
-3.50%
P/S Ratio
58.16
Revenue / Employee
$51.77K
Employees
90
Market Cap
280.00M GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.66M | -169.00K | -3.50% |
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | 20.75M | 18.21M | 718.46% |
| Dec 31, 2017 | 2.54M | -1.90M | -42.79% |
| Dec 31, 2016 | 4.43M | -7.40M | -62.54% |
| Dec 31, 2015 | 11.83M | 9.61M | 432.31% |
| Dec 31, 2014 | 2.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Genus | 658.10M |
| Oxford Biomedica | 175.36M |
| Bioventix | 12.54M |
| Scancell Holdings | 4.71M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
| 4basebio | 781.00K |
| Avacta Group | 113.00K |
PureTech Health News
- 5 days ago - PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress - Business Wire
- 23 days ago - PureTech Health Earnings Call Transcript: H1 2026 - Transcripts
- 23 days ago - PureTech Health Quarterly report: H1 2026 - Filings
- 24 days ago - PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) - Business Wire
- 5 weeks ago - PureTech Health: Notice of Half-Yearly Results - Business Wire
- 7 weeks ago - PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress - Business Wire
- 3 months ago - PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Business Wire
- 3 months ago - PureTech entity Celea raises $180 million to move lung disease drug into late stage trial - Reuters